Fate Therapeutics, Inc.
$1.39
▼
-1.61%
2026-04-21 06:47:00
www.fatetherapeutics.com
NGM: FATE
Explore Fate Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$158.12 M
Current Price
$1.39
52W High / Low
$1.94 / $0.91
Stock P/E
—
Book Value
$1.8
Dividend Yield
—
ROCE
-52.22%
ROE
-51.84%
Face Value
—
EPS
$-1.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
161
Beta
2.24
Debt / Equity
37.58
Current Ratio
5.79
Quick Ratio
5.79
Forward P/E
-1.18
Price / Sales
21.69
Enterprise Value
$18.36 M
EV / EBITDA
-0.14
EV / Revenue
2.76
Rating
None
Target Price
$4.94
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 2. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 3. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 4. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 5. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 6. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 7. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.37 M | 1.74 M | 1.91 M | 1.63 M | 1.86 M |
| Operating Profit | -34.72 M | -34.73 M | -36.97 M | -41.28 M | -47.01 M |
| Net Profit | -32.37 M | -32.25 M | -34.07 M | -37.62 M | -52.15 M |
| EPS in Rs | -0.28 | -0.28 | -0.29 | -0.32 | -0.45 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.65 M | 13.63 M | 63.53 M | 96.3 M |
| Operating Profit | -147.7 M | -195.54 M | -190.51 M | -308.39 M |
| Net Profit | -136.31 M | -186.26 M | -160.93 M | -281.72 M |
| EPS in Rs | -1.17 | -1.6 | -1.38 | -2.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 318.94 M | 440.69 M | 506.22 M | 705.56 M |
| Total Liabilities | 111.75 M | 121.97 M | 137.8 M | 221.62 M |
| Equity | 207.18 M | 318.73 M | 368.42 M | 483.94 M |
| Current Assets | 208.7 M | 291.91 M | 331.54 M | 502.07 M |
| Current Liabilities | 36.07 M | 38.52 M | 39.09 M | 114.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -106.08 M | -122.87 M | -132.26 M | -248.21 M |
| Investing CF | 111.17 M | 12.22 M | 112.67 M | 166.75 M |
| Financing CF | 5.49 M | 99.89 M | 0.09 M | 9.21 M |
| Free CF | -112.04 M | -123.6 M | -138.42 M | -283.77 M |
| Capex | -5.95 M | -0.73 M | -6.15 M | -35.57 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -78.55% | -34.03% | — | — |
| Earnings Growth % | -15.74% | 42.88% | — | — |
| Profit Margin % | -1366.46% | -253.3% | -292.55% | — |
| Operating Margin % | -1434.52% | -299.86% | -320.23% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1295.41% | -271.09% | -305.95% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.